The cell and gene therapy (CGT) sector is expanding rapidly, with hundreds of clinical programmes advancing toward commercialisation worldwide. As viral vector manufacturing scales from clinical batches to commercial production, one of the most critical downstream processing challenges remains the efficient removal of residual host cell DNA (hcDNA). Regulatory agencies require that hcDNA levels in … Continue reading Provinase®: Endonuclease Solutions for Gene Therapy